VIA EDGAR
February 2, 2018
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Christine Westbrook
| Re: | Catalyst Biosciences, Inc. |
| Registration Statement on FormS-3 |
| FileNo. 333-222644 |
| Request for Acceleration of Effectiveness |
Dear Ms. Westbrook:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Catalyst Biosciences, Inc. a Delaware corporation (the “Company”), hereby requests that the Securities and Exchange Commission (“Commission”) take appropriate action to cause theabove-referenced Registration Statement to become effective at 4:00 PM Eastern Time on February 6, 2018, or as soon thereafter as practicable.
Please contact Stephen B. Thau of Morrison & Foerster LLP, counsel to the Company, at (650)813-5640 should you have any questions or require additional information regarding this request and to notify us that the Registration Statement has been declared effective pursuant to this acceleration request.
| Very truly yours, | ||
| CATALYST BIOSCIENCES, INC. | ||
| By: | /s/Fletcher Payne | |
| Name: | Fletcher Payne | |
| Title: | Chief Financial Officer | |
| cc: | Stephen B. Thau, Morrison & Foerster LLP |